The adverse reactions presented in this section have been reported from post marketing surveillance as well as from 2 studies with FEIBA for the treatment of bleeding episodes in pediatric and adult patients with hemophilia A or B and inhibitors to factors VIII or IX. One study also enrolled acquired hemophilia patients with factor VIII inhibitors (2 of 49 patients). The adverse reactions from a third study comparing prophylaxis with on-demand treatment have been added.
Frequency categories are defined according to the following convention: very common: ≥ 1/10; common: ≥ 1/100 to <1/10; uncommon: ≥ 1/1,000 to <1/100; rare: ≥ 1/10,000 to <1/1,000; very rare: < 1/10,000; unknown: cannot be estimated from the available data. (See table.)
Click on icon to see table/diagram/image
Class Reactions: Other symptoms of hypersensitivity reactions to plasma-derived products include lethargy and restlessness.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of FEIBA is important. It allows continued monitoring of the benefit/risk balance of FEIBA. Healthcare professionals are asked to report any suspected adverse reactions.
View ADR Monitoring Form